002626 Xiamen Kingdomway Group
- 14.36
- -0.25-1.71%
Xiamen Kingdomway Group News
[BT Financial Report Momentary Analysis] In-depth Analysis of Jin Dawei's 2023 Report: A Comprehensive Review of Financial Health
As a high-tech enterprise focusing on R&D, production and sales of health food (including health food ingredients and health food terminal products) and feed additives, Jin Dawei (stock code: 002626) has attracted market attention. The company's business is spread all over the world, mainly exports, covering the entire health food industry chain, including raw material supply, formulation production, brand operation and channel layout, showing the company's competitive advantage within the industry and the strategic vision of the global layout. Judging from the balance sheet, Jin Dawei's total assets fell slightly from 5.425 billion yuan at the beginning of the year to 5 at the end of the year
Is Xiamen Kingdomway Group (SZSE:002626) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Jin Dawei (002626.SZ): 2023 equity distribution of 10 distributions of 2 yuan Equity Registration Date June 5
On May 28, Ge Longhui (002626.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 2.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 609,934,771 shares. The share registration date for this equity distribution is June 5, 2024, and the ex-dividend date is June 6, 2024.
Jin Dawei (002626.SZ): Using synthetic biotechnology, it has been used in large-scale production of products such as Coenzyme Q10, NMN, ARA, etc.
Gelonghui, May 20, 丨 Jin Dawei (002626.SZ) said on the investor interactive platform that the company has used synthetic biotechnology for large-scale production of products such as coenzyme Q10, NMN, NADH, vitamin K2, nattokinase, PQQ, SAMe, DHA, ARA, etc., and also uses synthetic biology to lay out new products, such as astaxanthin, inositol, calcium pantothenate, glutathione, etc. The company will also use synthetic biotechnology to lay out biosubstitutes, such as alloxone sugar, tag sugar, etc.
Kim Dawei (002626.SZ): In the future, synthetic biotechnology will be used to lay out biosaccharides
Gelonghui, May 16, 丨 Jin Dawei (002626.SZ) held a performance briefing on May 16, 2024 to discuss “What products are the synthetic biotechnology currently used in the company, and what new products does it plan to use synthetic biotechnology to develop in the future?” The company replied that the company has used synthetic biotechnology in the production of products such as coenzyme Q10, NMN, NADH, vitamin K2, natto kinase, PQQ, adenosylmethionine, DHA, ARA, etc., and also uses synthetic biology to lay out new products, such as astaxanthin, inositol, calcium pantothenate, etc. In the future, the company will use synthetic organisms
Jin Dawei (002626.SZ): A number of new raw materials have entered the preparation stage for industrial production
Gelonghui May 16 | Jin Dawei (002626.SZ) held a performance briefing on May 16, 2024 to discuss “What technical reserves does the company have in the field of synthetic biology?” The company replied that the company has strong technical reserves and accumulation in the field of synthetic biological product manufacturing, and that the company has mastered the five core technologies of synthetic biological green manufacturing, microbial fermentation, chemical synthesis, natural product extraction, and microcapsule technology. The company has established a large-scale biological enzyme bank platform with in vitro biosynthesis and in vivo biosynthesis research and development capabilities. The company has created industrial strains, intelligent control of fermentation processes, and product application development
Kim Dawei (002626.SZ): Received 3 invention patents
Gelonghui, May 16, 丨 Jin Dawei (002626.SZ) announced that the company recently received a total of 3 invention patent certificates issued by the State Intellectual Property Office, namely a method for preparing vitamin K2 using microbial fermentation; a coenzyme Q10-lipoic acid phospholipid nanocomposite micelle and its preparation method and application; and a method for producing hyaluronic acid.
Kim Dawei | Frequent mergers and acquisitions, poor market capitalization, synthetic organisms, vitamins, NMN, and health products. Who will save them from their difficult performance?
Can performance be reversed again?
Xiamen Kingdomway Group's (SZSE:002626) Earnings Trajectory Could Turn Positive as the Stock Soars 11% This Past Week
It is doubtless a positive to see that the Xiamen Kingdomway Group Company (SZSE:002626) share price has gained some 32% in the last three months. But that is small recompense for the exasperating
Jin Dawei (002626.SZ): Net profit of 707.938 million yuan in the first quarter decreased by 18.58% year-on-year
On April 29, Ge Longhui (002626.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 743 million yuan, down 5.99% year on year; net profit attributable to shareholders of listed companies was 707.938 million yuan, down 18.58% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 697.157 million yuan, down 15.35% year on year; basic earnings per share were 0.12 yuan.
Jin Dawei (002626.SZ): “A method for preparing nicotinamide adenine dinucleotide” obtained an invention patent
Gelonghui, April 11 | Jin Dawei (002626.SZ) announced that the company's holding subsidiary Jiangsu Chengxin Pharmaceutical Co., Ltd., the company and its wholly-owned subsidiary Inner Mongolia Jindaway Pharmaceutical Co., Ltd., and its wholly-owned subsidiary Jindaway Biotechnology (Jiangsu) Co., Ltd. recently each received an invention patent certificate issued by the State Intellectual Property Office, which is a preparation method for nicotinamide adenine dinucleotide.
Calculating The Intrinsic Value Of Xiamen Kingdomway Group Company (SZSE:002626)
Key Insights Xiamen Kingdomway Group's estimated fair value is CN¥18.31 based on 2 Stage Free Cash Flow to Equity With CN¥14.95 share price, Xiamen Kingdomway Group appears to be trading close to it
Jindaway (002626.SZ): Jindaway vitamins gradually resume work and resume production
On April 1, Gelonghui (002626.SZ) announced that the company's wholly-owned subsidiary, Xiamen Jindawei Vitamin Co., Ltd. (Jindawei Vitamins for short), has gradually resumed work and resumed production. At around 9 a.m. on January 11, 2024, an explosion occurred in the Jindaway Vitamin sewage treatment tank space. After the accident, production of Jindaway Vitamins was discontinued. Currently, Jindawei Vitamin has gradually resumed work and production.
Jin Dawei (002626.SZ): Subsidiary “A pre-desalination process in propanedipeptide production” obtained an invention patent
Gelonghui, March 13, 丨 Jin Dawei (002626.SZ) announced that Jiangsu Chengxin Pharmaceutical Co., Ltd., a holding subsidiary of the company, recently received an invention patent certificate issued by the State Intellectual Property Office, which is a pre-desalination process in propanol dipeptide production.
Xiamen Kingdomway Sets Up US Joint Venture
Chinese bio-medical products manufacturer Xiamen Kingdomway Group (SHE:002626) established a joint venture in the US through subsidiary VitaBest Nutrition, according to a Monday disclosure published o
Jin Dawei (002626.SZ): Wholly-owned subsidiary plans to establish a joint venture in the US
Glonghui, March 11 | Jin Dawei (002626.SZ) announced that the company recently received a notice from VitaBest Nutrition, Inc., a wholly-owned US subsidiary, to jointly invest and establish a joint venture with natural persons WONG KA HUNG and Pan Xinqi in California, USA. The main business of this joint venture is the production of softgel series products. The establishment of the company is conducive to expanding the company's product system, enhancing the competitiveness of the company's overseas business, and in line with the company's medium- to long-term development strategy.
Xiamen Kingdomway Group Company (SZSE:002626) Stock's On A Decline: Are Poor Fundamentals The Cause?
Xiamen Kingdomway Group (SZSE:002626) has had a rough three months with its share price down 21%. We decided to study the company's financials to determine if the downtrend will continue as the long
Xiamen Kingdomway to Buy US Nutritional Supplements Firm for $17 Million
Xiamen Kingdomway Group (SHE:002626) plans to acquire a US-based nutritional supplements company for $17.2 million, according to a recent filing. Kingdomway, through its US subsidiary Doctor's Best In
Xiamen Kingdomway Group (SZSE:002626) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Kim Dawei (002626.SZ): US subsidiary DRB plans to buy 100% of Activ's shares for about $17.2 million
Glonghui, Feb. 4 | Jin Dawei (002626.SZ) announced that the company's US subsidiary Doctor's Best Inc. (DRB) recently cooperated with US Viactiv Nutritionals, Inc. (hereinafter referred to as Viactiv), Activ Nutritionals, LLC (hereinafter referred to as Activ or Target Company) and Guardion Health Sciences, Inc. (Viactiv parent company for short) Guardion) signed “Shares”
Analysis
Price Target
No Data
